Abdominal aortic aneurysm and cerebral aneurysm present different pathological evolutions and responses to pharmacological therapy

Medical Hypotheses

Volumn 68, Issue 3, 2007, Pages 601-606

  Zhou, Xin ^a,b   Ji, Wen Jie ^c   Tu, Yue ^b   Yao, Min ^b   Li, Yu Ming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MATRIX METALLOPROTEINASE;

ABDOMINAL AORTA ANEURYSM; ANEURYSM RUPTURE; ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; HEMODYNAMICS; HYPERTENSION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE;

AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CEREBROVASCULAR CIRCULATION; ELASTICITY; HUMANS; INTRACRANIAL ANEURYSM; MODELS, CARDIOVASCULAR;

EID: 33845956098     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.06.062     Document Type: Article

References (57)

1. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. Br Med J 2002;325(7373):1135.
2. Vorp D.A., and Vande Geest J.P. Biomechanical determinants of abdominal aortic aneurysm rupture. Arterioscler Throm Vas Biol 25 8 (2005) 1558-1566
3. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 111 6 (2005) 816-828
4. Perlstein T.S., and Lee R.T. Smoking, metalloproteinases, and vascular disease. Arterioscler Throm Vas Biol 26 2 (2006) 250-256
5. Sluijter J.P., de Kleijn D.P., and Pasterkamp G. Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc Res 69 3 (2006) 595-603
6. Eliason J.L., Hannawa K.K., Ailawadi G., et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 112 2 (2005) 232-240
7. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110 5 (2002) 625-632
8. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 1 (2005) 1-31
9. Wilson W.R., Anderton M., Schwalbe E.C., et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113 3 (2006) 438-445
10. Silence J., Collen D., and Lijnen H.R. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ Res 90 8 (2002) 897-903
11. Verrecchia F., Chu M.L., and Mauviel A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276 20 (2001) 17058-17062
12. Dai J., Losy F., Guinault A.M., et al. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. Circulation 112 7 (2005) 1008-1015
13. Petrinec D., Liao S., Holmes D.R., Reilly J.M., Parks W.C., and Thompson R.W. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23 2 (1996) 336-346
14. Boyle J.R., McDermott E., Crowther M., Wills A.D., Bell P.R., and Thompson M.M. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 27 2 (1998) 354-361
15. Sho E., Chu J., Sho M., et al. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J Vasc Surg 39 6 (2004) 1312-1321
16. Prall A.K., Longo G.M., Mayhan W.G., et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg 35 5 (2002) 923-929
17. Mosorin M., Juvonen J., Biancari F., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 34 4 (2001) 606-610
18. Curci J.A., Mao D., Bohner D.G., et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31 2 (2000) 325-342
19. Baxter B.T., Pearce W.H., Waltke E.A., et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg 36 1 (2002) 1-12
20. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69 3 (2006) 677-687
21. Sukhija R., Aronow W.S., Sandhu R., Kakar P., and Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 97 2 (2006) 279-280
22. Yoshimura K., Aoki H., Ikeda Y., et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11 12 (2005) 1330-1338
23. Verma S., and Lindsay T.F. Regression of aortic aneurysms through pharmacologic therapy?. N Engl J Med 354 19 (2006) 2067-2068
24. Wang Y.X., Martin-McNulty B., da Cunha V., et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation 111 17 (2005) 2219-2226
25. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113(6):e85-151.
26. Gould D.B., Phalan F.C., van Mil S.E., et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 354 14 (2006) 1489-1496
27. Markus H.S., and Alberts M.J. Update on genetics of stroke and cerebrovascular disease 2005. Stroke 37 2 (2006) 288-290
28. Juvela S., and Kase C.S. Advances in intracerebral hemorrhage management. Stroke 37 2 (2006) 301-304
29. Viswanathan A., and Chabriat H. Cerebral microhemorrhage. Stroke 37 2 (2006) 550-555
30. Suarez J.I., Tarr R.W., and Selman W.R. Aneurysmal subarachnoid hemorrhage. N Engl J Med 354 4 (2006) 387-396
31. Weitzman D., and Goldbourt U. The significance of various blood pressure indices for long-term stroke, coronary heart disease, and all-cause mortality in men: the Israeli ischemic heart disease study. Stroke 37 2 (2006) 358-363
32. Nahed B.V., DiLuna M.L., Morgan T., et al. Hypertension, age, and location predict rupture of small intracranial aneurysms. Neurosurgery 57 4 (2005) 676-683 discussion 676-683
33. Inci S., and Spetzler R.F. Intracranial aneurysms and arterial hypertension: a review and hypothesis. Surg Neurol 53 6 (2000) 530-540 discussion 532-540
34. Kataoka K., Taneda M., Asai T., and Yamada Y. Difference in nature of ruptured and unruptured cerebral aneurysms. Lancet 355 9199 (2000) 203
35. Ohashi Y., Horikoshi T., Sugita M., Yagishita T., and Nukui H. Size of cerebral aneurysms and related factors in patients with subarachnoid hemorrhage. Surg Neurol 61 3 (2004) 239-245 discussion 237-245
36. Zhang D., Zhao J., Sun Y., et al. Pathological observation of brain arteries and spontaneous aneurysms in hypertensive rats. Chin Med J (Engl) 116 3 (2003) 424-427
37. Guerreiro N.E., Colli B.O., Carlotti Jr. C.G., and Chimelli L. Experimental microaneurysms in rats: I. model for induction. Surg Neurol 62 5 (2004) 406-412
38. Kleinpeter G. Why are aneurysms of the posterior inferior cerebellar artery so unique? Clinical experience and review of the literature. Minim Invasive Neurosurg 47 2 (2004) 93-101
39. Horie N., Takahashi N., Furuichi S., et al. Ruptured aneurysm at the choroidal branch of the posterior inferior cerebellar artery: a case report and review of the literature. Surg Neurol 60 6 (2003) 540-544
40. McLaughlin N., and Bojanowski M.W. Ruptured aneurysm at the choroidal branch of the posterior inferior cerebellar artery: a case report, review of the literature and proposed pathogenesis. Br J Neurosurg 19 3 (2005) 250-253
41. Maeda K., Fujimaki T., Morimoto T., and Toyoda T. Cerebral aneurysms in the perforating artery manifesting intracerebral and subarachnoid haemorrhage-report of two cases. Acta Neurochir (Wien) 143 11 (2001) 1153-1156
42. Bruno G., Todor R., Lewis I., and Chyatte D. Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg 89 3 (1998) 431-440
43. Gaetani P., Rodriguez y., Baena R., Tartara F., et al. Metalloproteases and intracranial vascular lesions. Neurol Res 21 4 (1999) 385-390
44. Ohkuma H., Suzuki S., Fujita S., and Nakamura W. Role of a decreased expression of the local renin-angiotensin system in the etiology of cerebral aneurysms. Circulation 108 7 (2003) 785-787
45. Slowik A., Borratynska A., Pera J., et al. II Genotype of the angiotensin-converting enzyme gene increases the risk for subarachnoid hemorrhage from ruptured aneurysm. Stroke 35 7 (2004) 1594-1597
46. Tsunemi K., Takai S., Nishimoto M., et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 25 6 (2002) 817-822
47. Daugherty A., Manning M.W., and Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 11 (2000) 1605-1612
48. Wang Y.X., Martin-McNulty B., Freay A.D., et al. Angiotensin II increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice. Am J Pathol 159 4 (2001) 1455-1464
49. Moran C.S., McCann M., Karan M., Norman P., Ketheesan N., and Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 111 23 (2005) 3119-3125
50. Bouvet C., Gilbert L.A., Girardot D., deBlois D., and Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 3 (2005) 432-437
51. Laurent S., Boutouyrie P., and Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 45 6 (2005) 1050-1055
52. Kaufmann T.J., Marx W.F., and Kallmes D.F. A failure of matrix metalloproteinase inhibition in the prevention of rat intracranial aneurysm formation. Neuroradiology 48 3 (2006) 190-195
53. Futami K., Yamashita J., and Higashi S. Do cerebral aneurysms originate at the site of medial defects? Microscopic examinations of experimental aneurysms at the fenestration of the anterior cerebral artery in rats. Surg Neurol 50 2 (1998) 141-146
54. Ricci M.A., Strindberg G., Slaiby J.M., et al. Anti-CD 18 monoclonal antibody slows experimental aortic aneurysm expansion. J Vasc Surg 23 2 (1996) 301-307
55. Basalyga D.M., Simionescu D.T., Xiong W., Baxter B.T., Starcher B.C., and Vyavahare N.R. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 110 22 (2004) 3480-3487
56. Swamy S.M., Tan P., Zhu Y.Z., Lu J., Achuth H.N., and Moochhala S. Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun 314 3 (2004) 661-666
57. Zhou X., Li Y.M., Ji W.J., et al. Phenytoin can accelerate the healing process after experimental myocardial infarction?. Int J Cardiol 107 1 (2006) 21-29